Hormonal
Tirzepatide, a dual GLP-1/GIP receptor agonist administered once weekly, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity compared to placebo and other active comparators.
Tirzepatide is a once-weekly injection that helps your body manage blood sugar and lose weight more effectively than many existing treatments. It works by mimicking hormones that regulate appetite and insulin. You start with a low dose to minimize stomach upset and gradually increase it. It is approved for both type 2 diabetes and obesity management.
Tirzepatid je duální agonista receptorů pro glucagon-like peptid 1 (GLP-1) a glukózo-dependentní inzulinotropní polypeptid (GIP)... Po 40 týdnech užívání tirzepatid vykázal superioritu vůči placebu v ovlivnění HbA1c, glykemie nalačno, tělesné hmotnosti... Průměrný HbA1c klesl za 40 týdnů studie o 20–23 mmol/mol a vzrostl o 0,4 mmol/mol u placeba... v průběhu léčby došlo k redukci hmotnosti od 7 do 9,5 kg v závislosti na dávce.
Why this rating
Based on multiple Phase 3 randomized controlled trials (SURPASS 1-6, SURMOUNT 1-4) with large sample sizes and FDA/EMA approval.
Source
Tirzepatide - a promising medication for cardiovascular protection and treatment of Type 2 diabetes and obesity
Pavlína Piťhová · Vnitřní lékařství · 2025
DOI 10.36290/vnl.2025.009
More from this paper
- Tirzepatide provides cardiovascular protection by reducing major adverse cardiovascular events (MACE) and improving cardiovascular risk scores in patients with type 2 diabetes and obesity.Strong
- Tirzepatide improves kidney function markers (eGFR decline and albuminuria) and may slow the progression of chronic kidney disease in patients with type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →